Skip to main content

Central Precocious Puberty

0
Pipeline Programs
3
Companies
9
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

Takeda
TakedaTOKYO, Japan
3 programs
EnantoneN/A2 trials
LeuprorelinPHASE_42 trials
Leuprorelin Acetate Depot 3MPHASE_41 trial
Active Trials
NCT02993926Completed108Est. Sep 2018
NCT02085252Completed116Est. Nov 2016
NCT02427958Completed307Est. Nov 2018
+2 more trials
Debiopharm
DebiopharmSwitzerland - Lausanne
2 programs
Debio 4326PHASE_31 trial
TriptorelinPHASE_31 trial
Active Trials
NCT06129539Active Not Recruiting56Est. Feb 2028
NCT01467882Completed44Est. Jul 2014
Ipsen
IpsenChina - Tianjin
2 programs
Triptorelin PamoatePHASE_31 trial
Triptorelin pamoate 15mgPHASE_31 trial
Active Trials
NCT05029622Completed66Est. Feb 2023
NCT04736602Completed32Est. Sep 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
TakedaLeuprorelin Acetate Depot 3M
TakedaLeuprorelin
DebiopharmDebio 4326
IpsenTriptorelin Pamoate
IpsenTriptorelin pamoate 15mg
TakedaEnantone
DebiopharmTriptorelin
TakedaLeuprorelin
TakedaEnantone

Clinical Trials (9)

Total enrollment: 1,150 patients across 9 trials

NCT05341115TakedaLeuprorelin Acetate Depot 3M

A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Start: Mar 2023Est. completion: Mar 202580 patients
Phase 4Completed

A Study to Assess the Safety and Efficacy of Leuprorelin in Central Precocious Puberty in Chinese Participants

Start: Aug 2015Est. completion: Nov 2018307 patients
Phase 4Completed

A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pediatric Participants With Central Precocious Puberty (LIBELULA™ Clinical Trial)

Start: Jul 2024Est. completion: Feb 202856 patients
Phase 3Active Not Recruiting
NCT05029622IpsenTriptorelin Pamoate

A Study to Assess the Efficacy and Safety of the Triptorelin 6-month Formulation in Paediatric Participants With Central Precocious Puberty.

Start: Aug 2021Est. completion: Feb 202366 patients
Phase 3Completed
NCT04736602IpsenTriptorelin pamoate 15mg

Efficacy and Safety Study of Triptorelin 3-Month Formulation in Chinese Children With Central Precocious Puberty.

Start: Mar 2021Est. completion: Sep 202232 patients
Phase 3Completed

A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer

Start: Jun 2013Est. completion: Nov 2016116 patients
Phase 3Completed

Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty

Start: Apr 2012Est. completion: Jul 201444 patients
Phase 3Completed

Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c

Start: Dec 1996Est. completion: Dec 2008341 patients
Phase 2Completed

A Study to Assess the Safety and Efficacy of Enantone (Leuprorelin) in Central Precocious Puberty (CPP) Among Chinese Participants

Start: Jun 2017Est. completion: Sep 2018108 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.